Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Longevity & Anti-Aging

Humanin

Apoptosis regulator BAX

Evidence: Preclinical only Disclaimer: Critical Not FDA-approved

Mechanism & research context

Mitochondrial-derived peptide studied in neuroprotection and metabolic regulation; early correlational human data.

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

7 records
  • Live search Live search

    Live ClinicalTrials.gov search: Humanin

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT03431844 COMPLETED

    Prospective Clinical Observational Study of Humanin Isoforms in Cardiac Muscle and Blood Plasma and Their Association to Major Complications After Cardiac Operation

    Condition: Myocardial Ischemia; Coronary Artery Bypass Surgery

    Sponsor: University of Tartu

    Open on ClinicalTrials.gov ↗
  • NCT04104958 UNKNOWN

    Identification of Recent Biomarkers in Polycystic Ovary Syndrome Patients as a Predictors of IVF Outcome

    Condition: Polycystic Ovary Syndrome

    Sponsor: Assiut University

    Open on ClinicalTrials.gov ↗
  • NCT05506228 RECRUITING

    How Are the Muscles Affected in Cerebral Palsy? A Study of Muscle Biopsies Taken During Orthopaedic Surgery of Children With Cerebral Palsy and Typically Developed Children (Control).

    Condition: Cerebral Palsy; Muscle; Muscle Contracture; Muscle Spasticity

    Sponsor: Eva Ponten

    Open on ClinicalTrials.gov ↗
  • NCT06105229 UNKNOWN

    Clinical Value of Plasma Humanin in Acute Kidney Injury

    Condition: Acute Kidney Injury

    Sponsor: Guangdong Provincial People's Hospital

    Open on ClinicalTrials.gov ↗
  • NCT06125249 UNKNOWN

    Humanin's Value for Early Diagnosis and Short-term Prognosis in Patients With AKI After Heart Transplantation

    Condition: Acute Kidney Injury; Heart Transplant Surgery

    Sponsor: Li zhilian

    Open on ClinicalTrials.gov ↗
  • NCT07438002 NA RECRUITING

    Effect of Exercise in Patients With Chronic Kidney Disease: TONE Trial

    Condition: Chronic Kidney Disease

    Sponsor: Casa di Cura Dott. Pederzoli

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Humanin yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Humanin, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Humanin. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.